Sartorius Looks Ahead to Sustained, Highly Profitable Growth – Sales Revenue to Rise to around 4 Billion Euros by 2025
Sartorius, a leading international technology partner of the biopharmaceutical industry and research laboratories, intends to continue on its profitable growth track over the long term. According to its new medium-term targets that will be presented today at the company’s annual press conference and its Capital Markets Day, the Group expects to achieve sales of around 4 billion euros in 2025. Management’s plan is to achieve around two-thirds of this growth organically while around one-third is to be generated by acquisitions.
Accordingly, the Group’s underlying EBITDA margin is forecasted to rise by 2025 to around 28%. The Bioprocess Solutions Division is expected to grow to around 2.8 billion in sales revenue with an underlying EBITDA margin of around 30% by 2025; for the Lab Products & Services Division, sales revenue of around 1.2 billion euros and an EBITDA margin of about 25% are projected for the full year of 2025. (All figures of the mid-term guidance given in constant currencies.)
“Our targets remain ambitious because we have positioned ourselves well for the future and address a market with sustainable, fundamental growth drivers,” said Group CEO Dr. Joachim Kreuzburg. “We assume that demand for biopharmaceutical drugs will continuously increase due to a growing and aging population, improved access to medicines in emerging countries, a rapidly expanding market for biosimilars and also due to completely new, emerging treatment options such as cell-based therapies. In this respect, the Asian market will play an increasingly important role, primarily China. We positioned ourselves with our two divisions as a global strategic partner of the biopharma sector so that we should sustainably benefit from these trends. With our broad and innovative product portfolio and the early expansion of our production capacities, we are well prepared for further growth.”
Business development of the Sartorius Group in 2017
The groundwork for reaching the Group’s targets has been laid: In 2017, Sartorius achieved an increase in sales revenue by 9.3% in constant currencies to 1,404.6 million euros, up from 1,300.3 million euros a year ago (reported: +8.0%), and increased its underlying earnings to 353.2 million euros. Organic growth and acquisitions contributed almost equally to growth.
"In 2017, Sartorius continued on its profitable growth track, executed two strategically important acquisitions, moved forward on its extensive investment program and created a considerable number of new jobs," commented Kreuzburg. "By entering the business field of bioanalytics in the Lab Products & Services Division, we opened a new chapter and reached a substantially higher level of growth and profit margin. Given the high revenue base after two years of exceptionally strong expansion and despite several dampening effects, our bioprocess business increased yet again. For 2018, we will continue to pursue our targets of achieving significant profitable growth, investing extensively in innovations and capacities and of creating additional jobs."
All regions contributed to this strong performance. Asia|Pacific expanded the most, with sales up 22.5% to 344.6 million euros. EMEA2 grew by 6.8% to 604.5 million euros. In the Americas, the region in which Sartorius had recorded especially strong gains over the past years, sales revenue rose year over year by 3.5% to 455.5 million euros.
Order intake for the Sartorius Group was up 13.7% in 2017, increasing more strongly than sales. Demand in its bioprocess business picked up significantly, especially in the second half.
(All growth rates for the regions and order intake in constant currencies)
Underlying EBITDA rose by 8.5% in the reporting period, despite unfavorable currency effects, to 353.2 million, and the respective margin edged up slightly from 25.0% to 25.1%. Relevant net profit3 for the Group increased 8.6% from 132.6 million euros to 144.0 million euros. Consolidated earnings per ordinary share rose to 2.10 euros (prior-year period: 1.93 euros) and per preference share, 2.11 euros (prior-year period: 1.94 euros).
The Group's key financial indicators continued to remain at a strong level, even after the two acquisitions executed in 2017. At the end of the reporting period, the company's equity ratio was 35.1%, and the ratio of net debt to underlying EBITDA stood at 2.5 (Dec. 31, 2016: 42.0% and 1.5, respectively).
Capital expenditures rose in the reporting year from 152.1 million euros to 209.4 million euros due to considerable expansion of the Group's global infrastructure; the respective ratio of capital expenditures to sales revenue was 14.9% relative to 11.7% a year ago.
Sartorius employed 7,501 people worldwide at year-end 2017, thus 8.5% or 590 more people than a year earlier. Of this number, 214 employees joined the company due to acquisitions.
Business development of the divisions
The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacture of biopharmaceuticals, recorded full-year sales growth of 4.9% in constant currencies to 1,010.3 million euros in 2017, relative to a very high prior-year revenue base, with acquisitions accounting for around one percentage point of growth in this sales figure. The division's business development was dampened by several simultaneous and temporary effects, primarily impacting the Americas region. Thus, temporary bottlenecks in supply for its business with cell culture media, inventory destocking by a few large customers and an interruption in production at the plant in Puerto Rico following Hurricane Maria all had an impact. Order intake rose at a rate nearly twice as fast as sales revenue, reaching 9.7% in constant currencies after significant double-digit gains in the second half of the year.
The division's underlying EBITDA rose by 3.3% to 282.4 million euros. Despite unfavorable currency effects, the corresponding margin was 28.0%, at the prior-year level.
The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and in life science research, recorded exceptionally dynamic growth due to its strong organic development and to a further acquisition in bioanalytics. The division's sales revenue rose by 22.0% to 394.2 million euros (reported: +21.2%), with around 14 percentage points of this expansion attributed to acquisitions. All regions and product areas contributed to this strong growth. In Lab Products & Services, order intake likewise increased at a faster pace than did sales, rising year over year by 25.8%.
Underlying EBITDA for the division also rose overproportionately with respect to sales, by 36.3% to 70.8 million euros. The division's margin climbed to 18.0% relative to 16.0% in the prior year.
Positive effects expected from U.S. tax reform
The U.S. tax reform approved in December 2017, which essentially lowers the U.S. corporate tax rate from 35% to 21%, resulted in the Sartorius Group in positive, non-cash extraordinary items of around 16 million euros during the reporting year, due to re-evaluation of deferred tax liabilities in the U.S. The corporate tax rate for the Group significantly decreased as a result of this effect from 29.0% a year earlier to 19.8% in the year under review.
A reduction in Sartorius' corporate tax rate by about 2 percentage points to around 27% is expected from 2018 onwards as a future effect. Since the changes in American tax legislation are very extensive, and further explanations and instructions for application by the U.S. tax authorities are still pending, this estimate is to be considered tentative.
Positive outlook for fiscal 2018
Sartorius again expects considerable profitable growth for the current year and therefore sees itself on track to reach its current mid-term targets set for 2020. Management thus projects that Group sales revenue for the full year will grow by about 9% to 12% and the company's underlying EBITDA margin will increase by about half a percentage point over the prior-year figure of 25.1%. The capex ratio will remain at the previous year's level of around 15%.
In view of the two divisions, management anticipates that sales for Bioprocess Solutions will grow by about 8% to 11% and that the division's underlying EBITDA margin will rise by around half a percentage point compared with the prior-year figure of 28.0%. For the Lab Products & Services Division, Sartorius projects that sales will grow approx. 12% to 15% and the division's underlying EBITDA margin will increase by about one percentage point (2017: 18.0%).
Because of the latest currency developments, reported figures in actual currencies might differ from constant currency guidance, and additional details will be provided as 2018 progresses.
1 Sartorius uses underlying EBITDA (earnings before interest,
taxes, depreciation and amortization and adjusted for extraordinary
items) as the key profitability indicator
2 EMEA = Europe | Middle East | Africa
3 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
Current image files
Upcoming financial dates
April 5, 2018 Annual Shareholders' Meeting
April 24, 2018 Publication of first-quarter figures (January to March 2018)
July 24, 2018 Publication of first-half figures (January to June 2018)
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.4 billion euros in 2017. More than 7,500 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.
Key Performance Indicators for Fiscal 2017
|Sartorius Group||Bioprocess Solutions||Lab Products & Services|
|in millions of € (unless otherwise specified)||2017||
|Δ in % Reported||Δ in % cc1||
|Δ in % Reported||Δ in % cc1||
|Δ in % Reported||Δ in % cc1|
|Sales Revenue and Order Intake|
|- Asia | Pacific2||344.6||285.8||20.6||22.5||239.4||193.5||23.7||25.3||105.2||92.3||14.0||16.6|
|EBITDA margin3 in %||25.1||25.0||28.0||28.0||18.0||16.0|
|Net profit for the period4||144.0||132.6||8.6|
|Financial Data per Share|
|Earnings per ordinary share4 in €||2.10||1.93||8.6|
|Earnings per preference share4 in €||2.11||1.94||8.6|
1 In constant currencies abbreviated as "cc"
|2 Acc. to the customer's location|
|4 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.|
Petra Kirchhoff, +49 (0)551.308.1686
Vice President of Corporate Communications and IR
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Mavenir Wins 5G Asia “Best RAN Product” Award24.9.2018 13:00 | Pressemelding
Mavenir, focused on transforming mobile network economics for Communications Service Providers (CSPs), is proud to be awarded 5G Asia’s 2018 ‘Best RAN Product’ award for its innovative, flexible Cloud RAN solution. Mavenir’s Cloud RAN can save operators 37% in total cost of ownership (TCO) over a five-year period due to a 49% reduction in capex and a 31% annual reduction in opex1. The TechXLR8 5G Asia Awards were announced on September 19th in Singapore and celebrate excellence in the APAC’s technology and telecommunications community with the goal of showcasing the year’s greatest industry achievements. Mavenir’s Cloud RAN extends virtualization of the network to the edge and provides strategic differentiation by enabling the remote radio units (RRUs) to interwork with the virtualized cloud base band unit (vBBU) over ethernet fronthaul (FH) to the xRAN specification published early this year. Combined with network slicing support and flexibility for the vBBU to be co-located with the
ARTMS’ QUANTM Irradiation System™ to Be Featured at Two International Conferences in September24.9.2018 13:00 | Pressemelding
ARTMS Products, Inc. announced today that it has been invited to present at the National Nuclear Security Administration’s 2018 Mo-99 Topical Meeting on Tuesday, September 25th and the Third International Symposium on Technetium and other Radiometals in Chemistry and Medicine on Thursday, September 27th. Joel Kumlin will present at the 2018 Mo-99 Topical Meeting in Knoxville, TN, during Session 7, Production Projects and Technologies II, at 13:00EDT on September 25th. Mr. Kumlin will be discussing progress on implementation of the ARTMS QUANTM Irradiation System™ for producing technetium-99m. The QIS™ combines local production control and a cost-effective, easy-to-use solid target system for the production of Tc-99m on most cyclotron systems. ARTMS recently announced that the QIS™ received CE mark approval and has been installed in a number of countries throughout the world. ARTMS also announced that Dr. Paul Schaffer, CTO, has been invited to present at the Third International Symposi
Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C24.9.2018 12:30 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch at a list price of $24,000 for the most common course of therapy and will be available in January 2019. Since the launch of Gilead’s first HCV medication in 2013, the average price paid for each bottle of medicine in the United States has decreased by more than 60 percent off of the public list prices, across health insurers and government payers. Due to the complexity and structure of the U.S. healthcare system, however, these discounts provided by Gilead may not always translate into lower costs for patients. Further, existing contracts, together with laws associated with government pricing policies, make it cha
GSMA To Showcase Mobile’s Increasing Impact on Sustainable Development During UN General Assembly Week24.9.2018 12:00 | Pressemelding
The GSMA will represent the global mobile industry at the 73rd session of the UN General Assembly (UNGA) being held in New York this week, advancing the leading role the sector is playing in meeting the UN Sustainable Development Goals (SDGs). Over the coming week, the GSMA will be participating in a wide range of activities with several high-profile partners and providing a critical platform for dialogue between mobile industry leaders, heads of state, global leaders and governments to further accelerate mobile’s contribution to the SDGs. “The GSMA will be in UNGA for the third year running to demonstrate how the global mobile industry is strengthening its commitment to improving lives around the world, as we enter a critical period in the delivery of the UN’s ambitious 2030 Agenda,” said Mats Granryd, Director General of the GSMA. “As the leading forum for international political cooperation, UNGA give us a unique opportunity to showcase how mobile’s unprecedented global scale is con
BolySolar Announcing Launch of BolySolar Tree24.9.2018 11:00 | Pressemelding
Bolymedia Holdings Co. Ltd., a global high-tech company headquartered in Silicon Valley, is pleased to announce its fifth patented renewable energy product – BolySolar Tree - at the Anaheim, California SPI to be held on September 24-27, 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005050/en/ BolySolar Tree (Graphic: Business Wire) BolySolar is a complete set of solar technologies and products that will revolutionize the entire energy industry. At SPI this month, the company will be showcasing its fifth product from its growing line of solar technologies - the BolySolar Tree. The diagram shows the basic design of the BolySolar Tree. The basic idea of the BolySolar Tree is to allow double-sided solar energy utilization with the help of mirrors, thereby reducing solar energy system costs and generating electricity for a longer duration. Compared to the conventional fixed-mount PV panel systems or tracker-mounted P
The 9th Edition of Tour of China 2018 Comes to an End24.9.2018 10:45 | Pressemelding
The sixteen-day Tour of China 2018 is concluded in Anshun, Guizhou Province on 23rd September, as the 13th stage witnesses the victory of Jakub Mareczko from Wilier Triestina – Selle Italia. The last stage in Anshun is a circuit race of 127.8 kilometers with two sprints and one KOM of Category 4. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005421/en/ The riders are crossing the finishing line. (Photo: Business Wire) The stage remained exciting and unpredictable due to little difference between riders’ results after the 12th stage. No rabbit group was formed even after 40 kilometers, though riders had never stopped breaking out from the peleton since race started. As the peleton kept its pace, Luke Mudgway from H&R Block Pro Cycling Team led the rabbit group of four who worked together quite well, with the gap of 1 minute 50 seconds. The gap narrowed, however, as the peleton started to chase with 30 kilometers to go,